Sampling You Can Trust
Convenient and quantitative blood sampling at the fingertip for everyone, everywhere at anytime.
We believe Home Sampling has a key role to play in helping health authorities and healthcare providers meet the challenges of this unprecedented crisis. Large-scale antibody testing is required to generate essential epidemiologic data for better risk management and to enable more targeted and effective government intervention. Whether you need devices to validate your analytical method, run a study or launch a new project, contact us to learn more about how the Capitainer qDBS device can help.
Easy To Use
Convenient and quantative blood sampling ay the fingertip for everyone, everywhere at anytime. Enables easy and accurate sampling by non-healthcare professionals.
Precise & Accurate
Delivers similar precision and accuracy to assays as from venous blood sampling. Exact sample volume of 10 μl with low CV, independent of haematocrit.
Next generation of the established
standard for DBS blood sampling –
Capitainer qDBS, the blood collection device for microsampling with predefined blood volume.
Capitainer raises further SEK31 million to meet anticipated demand for qDBS dried blood spot sampling system as COVID-19 vaccine programs are rolled out
Stockholm, January 19, 2021: Swedish medtech start-up Capitainer today announced that it has closed a share issue of SEK31 million to roll out its new qDBS dried blood spot testing system.
Capitainer awarded ISO 13485:2016 as interest grows in qDBS testing for COVID-19 and other challenging applications
Stockholm, November 11, 2020: Capitainer AB, a medtech company committed to making Dried Blood Spot testing universal, is pleased to...
Capitainer inks European and Asia Pacific distribution deal with Speciality Diagnostix for qDBS dried blood spot sampling system
Stockholm, September, 2020: Swedish med-tech start-up Capitainer today announced it has signed a distribution deal with Speciality...